Characteristics of study patients at baseline and of completers at the end of the trial
| Characteristic | Placebo (n=59) | Amitriptyline (n=59) | Melatonin (n=60) |
|---|---|---|---|
| Age—year (SD) baseline/end of trial | 36.6 (13.7)/36.1 (13.2) | 37.2 (11.2)/36.9 (13) | 36.9 (10.1) 36.5 (12.1) |
| Sex—N (%) women baseline/end of trial | 45 (76.3)/32 (76.2) | 44 (74.6)/30 (75) | 44 (73.3)/33 (73.3) |
| BMI baseline/end of trial, kg/m2 | 24.6 (4.0)/24.9 (3.8) | 23.9 (4.3)/24.3 (4.1) | 24.3 (4.9)/24.1 (4.7) |
| History of migraine—years (SD) baseline/end of trial | 20.2 (10.6)/21.1 (9.6) | 24.1 (9.1)/23.6 (9.5) | 23.2 (11.0)/21 (9.8) |
| Headache frequency (number of headache days)* | 7.3 (3.1) | 7.2 (2.5) | 7.3 (2.8) |
| Mean attack duration*—hours (SD) | 18.7 (17.3) | 16.7 (12.0) | 18.1 (13.8) |
| Mean headache intensity (0–10)* | 6.6 (1.4) | 7.0 (2.1) | 7.1 (1.9) |
| Aura—N (%) baseline/end of trial | 9 (15.2)/7 (17.5) | 10 (16.9)/7 (16.6) | 13 (21.7)/8 (17.7) |
| Number of analgesic doses taken per week* | 4.2 (1.3) | 4.6 (1.7) | 4.5 (1.9) |
*At baseline (4 weeks before start of study medication).
BMI, body mass index.